initiated a Phase I clinical investigation to evaluate the safety and applicability of these CAR-Ts in individuals with ovarian cancer (proficient in the expression of glypican 3 or mesothelin), as well as other advanced solid tumors (NCT03198546) (151). This evidence concerns the gene GPC3 and ovarian carcinoma.